Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis.

Singh AK. The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis. Clin J Am Soc Nephrol. 2010 Apr; 5(4):553-6.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.